TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03242954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autonomous minor consent
Description: Consent requirement where the participant is not required to get anyone's permission to participate in the trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adult permission required
Description: Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adult permission required
Description: Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parental permission required
Description: Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
Study: NCT04910178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 MG
Description: tablets to be taken orally twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: just starch tablets without any active agents
Study: NCT00906165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann® Bone Level SLActive Implant (4.1mm diameter)
Description: Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann® Bone Level SLActive Implant (4.1mm diameter)
Description: Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
Study: NCT03101540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation
Description: Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
Study: NCT01110005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D5 Lactated Ringer's Solution (D5LR)
Description: D5LR IV fluid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's Solution (LR)
Description: LR IV fluid
Study: NCT03242954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parental permission required
Description: Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
Study: NCT04091893

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care/wait list
Description: Individuals in this group can continue with their usual care (but receive no museum-based intervention)
Study: NCT04672109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
Study: NCT02807246

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Maflor®, Mamsel Pharmaceuticals, Turkey
Description: Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey)~Other Name: Maflor®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: drops of saline
Description: Dietary Supplement: Breast milk +drops of saline
Study: NCT01839357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
Study: NCT02678520

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-D Conformal Radiation Therapy
Description: Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily .
Study: NCT04091893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Rx
Description: Individuals in this group participate in a specialized tour of an art museum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Rx
Description: Individuals in this group participate in a specialized tour of an art museum
Study: NCT01246076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT00609830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Materials
Description: Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
Study: NCT02678520

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily .
Study: NCT04091893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artful Meditation
Description: Individuals in this group participate in a meditation and art appreciation program at an art museum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artful Meditation
Description: Individuals in this group participate in a meditation and art appreciation program at an art museum
Study: NCT03890809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration
Study: NCT02678520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex, Zoladex , Lupron
Description: Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Casodex, Zoladex , Lupron
Description: Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months.
Study: NCT01427621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic pre and postconditioning (RIPC)
Description: RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
Study: NCT00994474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional carbon dioxide laser treatment
Description: With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Er:YAG laser treatment
Description: The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
Study: NCT00609830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Materials Plus Physician Feedback
Description: Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
Study: NCT02441361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training will comprise aerobic and strength exercises
Study: NCT01930786

Intervention type: DRUG
Intervention: onabotulinumtoxinA
Description: onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
Study: NCT04883593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA103
Description: The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
Study: NCT00910975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (Copegus)
Description: Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
Study: NCT04883593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
Study: NCT01594177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 20 mg daily for 17 weeks (first two weeks every second day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
Study: NCT00609830

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Materials
Description: Participants received generic written educational materials about osteoporosis prevention.
Study: NCT04765293

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical Therapy Gravity strengthening exercises vs standard physical therapy
Study: NCT00609830

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Information
Description: Participants received no informational materials.
Study: NCT01349374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.
Study: NCT06249971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermal subsitute Glyaderm + skin graft
Description: A human donor-derived dermal substitute will be implanted together with a skin graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin graft alone
Description: Skin graft alone with no dermal substitute
Study: NCT04765293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical Therapy Gravity strengthening exercises vs standard physical therapy
Study: NCT03133663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrocardiogram group
Description: Experimental

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximeter and auscultation group
Description: Control
Study: NCT04668287

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Increasing self-esteem
Description: During 5 weeks, participants will be part of one of the working groups in which they'll be taught by a counselor about how a low self-esteem develops and what have to be done for improving self-esteem, based on the Melanie Fennel' model.
Study: NCT01945567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Up to 3 mA, 60 us, 130 Hz deep brain stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Up to 3 mA, 60 us, 130 Hz deep brain stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empirical unblinded deep brain stimulation programming
Study: NCT01503138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purpose-built intervention
Description: A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
Study: NCT01235676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: calorie restriction to reduce weight gain
Study: NCT00698321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STD prevention curriculum
Description: The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health promotion curriculum
Description: The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
Study: NCT03871049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with dexamethasone
Description: bupivacaine with dexamethasone
Study: NCT01235676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise to reduce weight gain
Study: NCT03871049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine
Study: NCT01682005

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
Study: NCT03752125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoid, caffeine
Description: 2 flavonoid/caffeine capsules before breakfast, 2 capsules before lunch

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules before breakfast, 2 capsules before lunch
Study: NCT04917783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passport Card
Description: After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Passport card
Description: After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
Study: NCT02773797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IN-DEX 1.0 mcg/kg, intranasal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IN-DEX 1.5 mcg/kg, intranasal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Saline
Study: NCT04057716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will be asked to restrict their time in bed to 8 hours each night for one week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will be asked to restrict their time in bed to 8 hours each night for one week.
Study: NCT03504826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL)
Description: Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
Study: NCT05332860

Intervention type: PROCEDURE
Intervention: Congenital Cardiovascular Surgery
Description: Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.

Intervention type: PROCEDURE
Intervention: Congenital Cardiovascular Surgery
Description: Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.
Study: NCT03777501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: non-random whole body vibration
Description: Each participant will receive the treatment about one hour after the administration of medicine. For non-random whole body vibration group, participants will be required to maintain the erect standing position on the vibratory platform and the frequency and amplitude of vibratory stimuli will be 6Hz and 3mm respectively. Each treatment includes five sessions and each session is composed of one minute whole body vibration and one minute rest.
Study: NCT05332860

Intervention type: PROCEDURE
Intervention: Congenital Cardiovascular Surgery
Description: Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.
Study: NCT03777501

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: occupational therapy
Description: Participants will receive the occupational therapy including dynamic balance training and functional ambulatory training.
Study: NCT03286972

Intervention type: DEVICE
Intervention: PET/MRI
Description: Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
Study: NCT01382160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg every two weeks, by subcutaneous way